Results showed that IRs of MACE and MI per 100 person-years increased corresponding with the patient’s 10-year ASCVD risk score. 2,3 However, a substantially significant increase was seen among those ...

While low-density lipoprotein (LDL) particles are much more abundant than lipoprotein(a) [Lp(a)] particles and carry the greatest overall risk for coronary heart disease (CHD), on a per-particle basis ...

Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its ...

Lipoprotein(a) levels, which are largely determined by genetics, appear to fluctuate over time, particularly in individuals with moderately elevated concentrations, a UK Biobank analysis shows. People ...

Even after stopping treatment with the novel small interfering RNA (siRNA) olpasiran (Amgen), patients experience sustained lowering of lipoprotein(a) for almost 1 year, according to new phase II data ...

Baseline lipoprotein a, or Lp(a), levels are strongly associated with major adverse cardiovascular events (MACE) in high-risk patients with elevated triglyceride levels receiving statin therapy, a new ...